IPP Bureau
WORK Medical scores regulatory approval for AI-powered blood analyzer
By IPP Bureau - January 01, 2026
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
By IPP Bureau - January 01, 2026
The study will run across 18 sites and enroll roughly 200 patients over 24 months
StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device
By IPP Bureau - January 01, 2026
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency
By IPP Bureau - January 01, 2026
The accelerated review covers WCK 5222 for multiple critical infections
Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
By IPP Bureau - January 01, 2026
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Co-Diagnostics scores major IP win in Australia with first patent for PCR platform
By IPP Bureau - January 01, 2026
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
By IPP Bureau - January 01, 2026
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
By IPP Bureau - December 31, 2025
The funding will accelerate Sinopia’s data-driven drug discovery efforts
GenSight Biologics gets early access nod for candidate gene therapy in Israel
By IPP Bureau - December 31, 2025
Applications include detailed scientific rationale and supporting clinical evidence
UK’s healthcare regulator warns against dangerous online weight-loss drugs
By IPP Bureau - December 31, 2025
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
Shenzhen Biopharma leader Lu Xianping wins EY Entrepreneur Of The Year 2025 award
By IPP Bureau - December 31, 2025
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers
By IPP Bureau - December 31, 2025
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Azenta to sell B Medical Systems for $63 million
By IPP Bureau - December 31, 2025
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance
By IPP Bureau - December 31, 2025
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
By IPP Bureau - December 31, 2025
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
